{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.1","upperLimit":"12.3","value":"2.3"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"8.4","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"description":"Serum M-protein response is defined as a decrease of greater than or equal to (\\>=) 50% in serum M-protein compared with baseline at 2 consecutive assessments.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 15 milligram per kilogram (mg/kg) of siltuximab as a 1-hour intravenous (IV) infusion every 4 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or the end of the study (up to 4 years after randomization of the last participant).","id":"OG000","title":"Siltuximab"},{"description":"Participants received placebo as a 1-hour IV infusion every 4 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or the end of the study (up to 4 years after randomization of the last participant).","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"ITT population included participants who were randomly assigned to siltuximab or placebo treatment group based on an IVRS.","reportingStatus":"POSTED","timeFrame":"Up to 4.7 Years","title":"Percentage of Participants With Serum M-protein Response","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}